Vybrique Film
Product Images NDC 71858-0205

26 FDA label images from Ibsa Pharma Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 26 technical images submitted to the FDA as part of the official labeling for Vybrique (NDC 71858-0205). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ibsa Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sildenafil Citrate Is Designated Chemically As 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine Citrate, Has The Molecular Formu (Vybrique Sildenafil Citrate Oral Film 01)

Sildenafil Citrate Is Designated Chemically As 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1h-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl]-4-methylpiperazine Citrate, Has The Molecular Formu (Vybrique Sildenafil Citrate Oral Film 01)
Chemical structure of sildenafil citrate, the active ingredient in Vybrique oral film tablets.*
FDA Label Image

Figure 1 (Vybrique Sildenafil Citrate Oral Film 02)

Figure 1 (Vybrique Sildenafil Citrate Oral Film 02)
Line graph depicting systolic blood pressure (mmHg) over time (hours) in young volunteers (18-45 years). It compares Sildenafil 100 mg oral film to placebo from pre-dose up to 10 hours post-dose, showing changes in systolic blood pressure for each group.*
FDA Label Image

Figure 2 (Vybrique Sildenafil Citrate Oral Film 03)

Figure 2 (Vybrique Sildenafil Citrate Oral Film 03)
A line graph showing systolic blood pressure (mmHg) over time (hours) in elderly (≥ 65 years) volunteers. The graph compares two groups: one receiving sildenafil 100 mg oral film and the other receiving placebo. The sildenafil group shows generally lower systolic blood pressure values compared to the placebo group throughout the 10-hour period.*
FDA Label Image

Blood (Blood Pressure Table Drug Listing)

FDA Label Image

Figure 3 (Vybrique Sildenafil Citrate Oral Film 04)

Figure 3 (Vybrique Sildenafil Citrate Oral Film 04)
A line graph showing the change in systolic blood pressure (SBP) over 8 hours postdose. The graph compares two treatments: Doxazosin + Placebo and Doxazosin + Sildenafil 25 mg. The y-axis represents the change in SBP (mmHg) and the x-axis represents time in hours postdose. The graph includes markers and lines for both treatment groups.*
FDA Label Image

Blood 50 mg (Blood Pressure 50mg Drug Listing)

FDA Label Image

Figure 4 (Vybrique Sildenafil Citrate Oral Film 05)

Figure 4 (Vybrique Sildenafil Citrate Oral Film 05)
Line graph depicting change in systolic blood pressure (mmHg) over time (hours) postdose. Two data series compare the effects of Doxazosin combined with Placebo versus Doxazosin combined with Sildenafil 50 mg, showing trends of blood pressure changes within an 8-hour postdose period.*
FDA Label Image

Blood 100 (Blood Pressure 100mg Drug Listing)

FDA Label Image

Figure 5 (Vybrique Sildenafil Citrate Oral Film 06)

Figure 5 (Vybrique Sildenafil Citrate Oral Film 06)
A line graph depicting the effect of dosing over time (hours) with two groups: Doxazosin plus Sildenafil 100 mg and Doxazosin plus Placebo. The vertical axis represents a measurement in mmHg, ranging approximately from -50 to 30, and the horizontal axis shows time after dosing from 0 to 8 hours.*
FDA Label Image

Table 4 (Table4)

FDA Label Image

Figure 6 (Vybrique Sildenafil Citrate Oral Film 07)

Figure 6 (Vybrique Sildenafil Citrate Oral Film 07)
A pharmacokinetic curve showing drug concentration (ng/mL) on the y-axis versus time (hours) on the x-axis. The graph depicts a rapid increase in concentration peaking around 2 hours, followed by a gradual decline over 24 hours.*
FDA Label Image

Table 5 (Table5 Drug Listing)

FDA Label Image

Figure 7 (Vybrique Sildenafil Citrate Oral Film 08)

Figure 7 (Vybrique Sildenafil Citrate Oral Film 08)
A pair of bar graphs comparing the effect of sildenafil and placebo on patients using the Rascina score. The left graph titled 'Effect of Sildenafil' shows the percentage of patients at each Rascina score from 0 to 5, with increasing scores associated with higher patient percentages, particularly for scores 4 and 5. The right graph titled 'Effect of Placebo' displays a more varied distribution of patient percentages across scores 0 to 5. Both graphs use a legend indicating score categories from 0 to 5.*
FDA Label Image

Figure 8 (Vybrique 09)

FDA Label Image

A (Vybrique Sildenafil Citrate Oral Film 0a)

A (Vybrique Sildenafil Citrate Oral Film 0a)
An illustration showing a hand holding a rectangular-shaped film strip, likely representing the oral film dosage form of Vybrique (sildenafil citrate). The image demonstrates how the film may be held prior to administration.*
FDA Label Image

B (Vybrique Sildenafil Citrate Oral Film 0b)

B (Vybrique Sildenafil Citrate Oral Film 0b)
Illustration showing hands peeling back the backing of a film strip, likely demonstrating how to open or handle a film dosage form.*
FDA Label Image

C (Vybrique Sildenafil Citrate Oral Film 0c)

C (Vybrique Sildenafil Citrate Oral Film 0c)
An instructional illustration showing two hands stretching an oral film product, possibly demonstrating how to handle or apply Vybrique oral film containing sildenafil citrate.*
FDA Label Image

D (Vybrique Sildenafil Citrate Oral Film 0d)

D (Vybrique Sildenafil Citrate Oral Film 0d)
An instructional illustration showing a person placing an oral film dosage form on their tongue. The film is being held by the person's hand near their mouth, demonstrating the proper method of administration.*
FDA Label Image

25 mg 4 Pack (25 4 Pack)

FDA Label Image

25 mg 8 Pack (25 8 Pack)

FDA Label Image

50 mg 4 Pack (50 4 Pack)

FDA Label Image

50 mg 8 Pack (50 mg 8 Pack)

FDA Label Image

75 mg 4 Pack (75 mg 4 Pack)

FDA Label Image

75 mg 8 Pack (75 mg 8 Pack)

FDA Label Image

100 mg 4 Pack (1000 mg 4 Pack)

FDA Label Image

100 mg 8 Pack (100 mg 8 Pack)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.